NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $63.56 +0.76 (+1.21 %) (As of 04/25/2019 11:48 AM ET)Previous Close$62.80Today's Range$62.04 - $63.7652-Week Range$60.32 - $79.61Volume263,926 shsAverage Volume6.74 million shsMarket Capitalization$81.03 billionP/E Ratio10.35Dividend Yield4.00%Beta1.16 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. Receive GILD News and Ratings via Email Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GILD Previous Symbol CUSIP37555810 CIK882095 Webwww.gilead.com Phone650-574-3000Debt Debt-to-Equity Ratio1.19 Current Ratio3.38 Quick Ratio3.30Price-To-Earnings Trailing P/E Ratio10.35 Forward P/E Ratio10.09 P/E Growth4.15 Sales & Book Value Annual Sales$22.13 billion Price / Sales3.66 Cash Flow$7.3821 per share Price / Cash Flow8.61 Book Value$16.65 per share Price / Book3.82Profitability EPS (Most Recent Fiscal Year)$6.15 Net Income$5.46 billion Net Margins24.65% Return on Equity37.03% Return on Assets12.44%Miscellaneous Employees11,000 Outstanding Shares1,274,900,000Market Cap$81.03 billion Next Earnings Date5/2/2019 (Confirmed) OptionableOptionable Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions What is Gilead Sciences' stock symbol? Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD." How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences? Gilead Sciences declared a quarterly dividend on Monday, February 4th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.63 per share on Thursday, March 28th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.97%. The ex-dividend date is Thursday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.57. View Gilead Sciences' Dividend History. How were Gilead Sciences' earnings last quarter? Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Monday, February, 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts' consensus estimates of $1.70 by $0.26. The biopharmaceutical company earned $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business's revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.78 EPS. View Gilead Sciences' Earnings History. When is Gilead Sciences' next earnings date? Gilead Sciences is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Gilead Sciences. How can I listen to Gilead Sciences' earnings call? Gilead Sciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. What price target have analysts set for GILD? 19 brokerages have issued 12-month price objectives for Gilead Sciences' shares. Their predictions range from $68.00 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $81.6250 in the next year. This suggests a possible upside of 28.7% from the stock's current price. View Analyst Price Targets for Gilead Sciences. What is the consensus analysts' recommendation for Gilead Sciences? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences. What are Wall Street analysts saying about Gilead Sciences stock? Here are some recent quotes from research analysts about Gilead Sciences stock: 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $87 Price Target. We do not think today’s announcement that GILD’s STELLAR3 study was unsuccessful will be met with much surprise after the previous STELLAR4 failure: no changes to our estimates. The fibrosis improvement was least for the high dose and greatest for the placebo with a p-value at the higher dose of 0.42 and at lower dose it was 0.93. After both STELLAR Ph3 readouts we are focused on how Gilead will advance its strategy in NASH; we think M&A could be a strategy." (4/25/2019) 2. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past six months." (4/23/2019) 3. Maxim Group analysts commented, "Gilead and Galapagos NV (GLPG – NR) reported positive data from two P3 studies of JAK1 inhibitor filgotinib in treating rheumatoid arthritis (RA); FINCH-1 and FINCH-3. Recall the FINCH-2 trial read-out in 3Q18. All three trials met their primary endpoints as well as multiple secondary endpoints." (3/29/2019) 4. Mizuho analysts commented, "We spoke to GILD. The company was able to confirm the title and time, and it noted that yes, this this is the pivotal DISCOVER trial, but couldn’t say exactly what data we will get. The company also confirmed that it’s a late-breaker and also an oral presentation. Clinicaltrials.gov still shows an active" status, but GILD noted to us that in general (not necessarily specific to this particular Descovy entry) clincaltrials.gov results can be presented at a lag. We note that oral presentations typically need to be informative, can’t just be baseline data, etc … our best guess is we’re getting both efficacy and safety data." (2/26/2019) Has Gilead Sciences been receiving favorable news coverage? News coverage about GILD stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gilead Sciences earned a news impact score of 1.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. Who are some of Gilead Sciences' key competitors? Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), Spark Therapeutics (ONCE), China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN) and Halozyme Therapeutics (HALO). What other stocks do shareholders of Gilead Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Celgene (CELG), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Walt Disney (DIS), Intel (INTC), NVIDIA (NVDA), Bank of America (BAC), AT&T (T) and Starbucks (SBUX). Who are Gilead Sciences' key executives? Gilead Sciences' management team includes the folowing people: Daniel O'Day, Chairman & Chief Executive OfficerRobin L. Washington, CFO, Principal Accounting Officer & Executive VPJohn G. McHutchison, Chief Scientific OfficerBrett A. Pletcher, Secretary, Chief Compliance Officer & Executive VPWilliam A. Lee, Executive Vice President-Research Who are Gilead Sciences' major shareholders? Gilead Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include First Manhattan Co. (0.16%), PGGM Investments (0.13%), Confluence Investment Management LLC (0.09%), Mondrian Investment Partners LTD (0.09%), Retirement Systems of Alabama (0.08%) and Factory Mutual Insurance Co. (0.07%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, Richard James Whitley and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences. Which institutional investors are selling Gilead Sciences stock? GILD stock was sold by a variety of institutional investors in the last quarter, including Avalon Advisors LLC, First Manhattan Co., Ferguson Wellman Capital Management Inc., LaFleur & Godfrey LLC, Busey Wealth Management, DNB Asset Management AS, First Hawaiian Bank and First National Bank of Mount Dora Trust Investment Services. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, John C Martin, John Francis Cogan and Richard James Whitley. View Insider Buying and Selling for Gilead Sciences. Which institutional investors are buying Gilead Sciences stock? GILD stock was acquired by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Pacer Advisors Inc., Mondrian Investment Partners LTD, Ellis Investment Partners LLC, Manning & Napier Group LLC, Exane Derivatives, PGGM Investments and Mercer Global Advisors Inc. ADV. View Insider Buying and Selling for Gilead Sciences. How do I buy shares of Gilead Sciences? Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Gilead Sciences' stock price today? One share of GILD stock can currently be purchased for approximately $63.42. How big of a company is Gilead Sciences? Gilead Sciences has a market capitalization of $80.85 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 11,000 workers across the globe. What is Gilead Sciences' official website? The official website for Gilead Sciences is http://www.gilead.com. How can I contact Gilead Sciences? Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected] MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 2,031 (Vote Outperform)Underperform Votes: 916 (Vote Underperform)Total Votes: 2,947MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/25/2019 by MarketBeat.com StaffFeatured Article: How is inflation measured?